S2090-S1232 (2024)
10.1002/trc2.12268 Alzheimers Dement
Over 48 weeks, Retatrutide outperformed both controls and dual agonists on weight and glucose control
Keywords , MASH , GLP-1 receptor agonists , hepatic steatosis , metabolic dysfunction , tirzepatide , semaglutide , survodutide 0 2 INTRODUCTION Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), has emerged as the predominant hepatic pathology worldwide, impacting roughly twenty-five percent of the adult population [1,2]
Vitamins, such as Vitamin C (ascorbic acid) and Vitamin E (tocopherol), possess strong antioxidant capabilities and can neutralize free radicals, protecting cells from oxidative damage